Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Introduces Rat miRNA Expression Assays
NanoString Introduces Rat miRNA Expression Assays   Kit Enables Profiling of More than 400 Rat miRNAs in a Single Tube without Amplification SEATTLE, Wash | August 5, 2011   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of
View HTML
Toggle Summary NanoString Embarks on First in Series of Clinical Studies for Breast Cancer Intrinsic Subtyping Assay
NanoString Embarks on First in Series of Clinical Studies for Breast Cancer Intrinsic Subtyping Assay   Study to Evaluate Disease Prognosis Using NanoString? PAM50-based Assay on the TransATAC Sample Set SEATTLE, Wash | August 3, 2011   -  NanoString Technologies, Inc., a privately held provider of
View HTML
Toggle Summary NanoString Offers New Tool for Analyzing 25 Leukemia Fusion Genes in a Single Reaction
NanoString Offers New Tool for Analyzing 25 Leukemia Fusion Genes in a Single Reaction   Multiplexed Assay Kit Provides Simple, Cost-effective Solution to Characterize Samples for Researchers SEATTLE, Wash | July 28, 2011   -  NanoString Technologies, Inc., a privately held provider of life science
View HTML
Toggle Summary Data Supporting Utility of the PAM50 Assay for Breast Cancer Gene Expression Profiling to be Presented at ASCO
Data Supporting Utility of the PAM50 Assay for Breast Cancer Gene Expression Profiling to be Presented at ASCO   NanoString Technologies Developing Distributed Assay Platform for Potential Use in Clinical Diagnostics SEATTLE, Wash., and CHICAGO, Ill | June 3, 2011   -  NanoString Technologies,
View HTML
Toggle Summary NanoString Technologies Introduces Multiplexed Assay Kit for Human Molecular Karyotyping
NanoString Technologies Introduces Multiplexed Assay Kit for Human Molecular Karyotyping   Panel Provides Cost Effective Way to Monitor Cell Line Quality, Perform Cytogenetics Research SEATTLE, Wash | February 22, 2011   -  NanoString Technologies, Inc., a privately held life sciences company
View HTML
Toggle Summary NanoString Technologies Names J. Wayne Cowens, M.D. Chief Medical Officer
NanoString Technologies Names J. Wayne Cowens, M.D. Chief Medical Officer   Veteran industry clinical oncologist to help build company's diagnostics pipeline SEATTLE, Wash | February 1, 2011   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution
View HTML
Toggle Summary NanoString Technologies Introduces Multiplexed Assay Kit for Mouse microRNA Analysis
NanoString Technologies Introduces Multiplexed Assay Kit for Mouse microRNA Analysis   SEATTLE, Wash | January 25, 2011   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological
View HTML
Toggle Summary NanoString Exclusively Licenses Worldwide Rights to Intrinsic Subtyping Gene Signature for Breast Cancer
NanoString Exclusively Licenses Worldwide Rights to Intrinsic Subtyping Gene Signature for Breast Cancer   Company Intends to Commercialize In Vitro Diagnostic Products on its nCounter Platform SEATTLE, Wash | December 6, 2010   -  NanoString Technologies, Inc., a privately held life sciences
View HTML
Toggle Summary NanoString Launches First Simple and Precise Approach to Detect Hundreds of Genetic Copy Variants in a Single Multiplexed Reaction
NanoString Launches First Simple and Precise Approach to Detect Hundreds of Genetic Copy Variants in a Single Multiplexed Reaction   WASHINGTON, D.C | November 2, 2010   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting
View HTML
Toggle Summary NanoString Technologies Appoints Industry Veteran Barney Saunders, Ph.D. as Chief Commercial Officer
NanoString Technologies Appoints Industry Veteran Barney Saunders, Ph.D. as Chief Commercial Officer   SEATTLE, Wash | October 6, 2010   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules
View HTML